Brokerages Set Plus Therapeutics, Inc. (NASDAQ:PSTV) PT at $56.40

Posted by George Bondi on Jun 19th, 2026

Shares of Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report) have earned an average rating of “Hold” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $56.40.

A number of research firms have commented on PSTV. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Ascendiant Capital Markets decreased their target price on shares of Plus Therapeutics from $65.00 to $57.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. D. Boral Capital reaffirmed a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st.

Get Our Latest Analysis on Plus Therapeutics

Plus Therapeutics Trading Down 2.6%

Shares of PSTV stock opened at $4.20 on Friday. The company’s 50-day moving average price is $5.79 and its 200-day moving average price is $8.05. The stock has a market cap of $28.90 million, a price-to-earnings ratio of -1.83 and a beta of 1.38. Plus Therapeutics has a twelve month low of $2.90 and a twelve month high of $23.42.

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.97 million. As a group, equities research analysts predict that Plus Therapeutics will post -3.76 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of PSTV. Jane Street Group LLC acquired a new position in Plus Therapeutics in the second quarter valued at about $41,000. Scientech Research LLC acquired a new position in Plus Therapeutics in the third quarter valued at about $100,000. Susquehanna International Group LLP acquired a new position in Plus Therapeutics in the third quarter valued at about $46,000. Geode Capital Management LLC lifted its position in Plus Therapeutics by 72.5% in the fourth quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after buying an additional 589,544 shares during the last quarter. Finally, L1 Global Manager Pty Ltd purchased a new stake in Plus Therapeutics during the fourth quarter worth about $1,167,000. Institutional investors and hedge funds own 3.28% of the company’s stock.

Plus Therapeutics Company Profile

(Get Free Report)

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.